Pharmaceuticals, Biotechnology and Life Sciences
Keytruda’s market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin’s lymphoma (NHL) patients.
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Osteoarthritis” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Osteoarthritis market,…
Syntrix Pharmaceuticals has started its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA, Merck’s anti-PD-1 therapy, as it dosed the first patient, it said Thursday.
-$MRK #MRK–At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term.
AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .
Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
First-Quarter 2019 Worldwide Sales Were $10.8 Billion, an Increase of8%; Sales Increased 11% Excluding Negative Impact from ForeignExchange; Growth Driven by Oncology and Vaccines
The safety profile of KEYTRUDA was consistent with thatpreviously observed in gastric cancer
many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes